Kymera Therapeutics Inc. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding agent coupled to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or polybromo-1 (PB1) protein targeting moiety via a linker reported to be useful for the treatment of cancer, viral infection, neurodegeneration, liver, metabolic, cardiovascular, genetic and inflammatory disorders, among others.
Researchers at Chia Tai Tianqing Pharmaceutical Group Co. Ltd. and Medshine Discovery Inc. have disclosed bicyclic substituted compounds acting as complement factor B (CFB) inhibitors reported to be useful for the treatment of Parkinson's disease.
Bridgebio Pharma Inc. has obtained FDA clearance for its IND application for BBO-8520, a first-in-class orally bioavailable and potent small-molecule direct inhibitor of KRAS G12C (ON) state. The company expects to begin enrolling patients with KRAS G12C mutant non-small-cell lung cancer (NSCLC) in the first half of this year.
Iaso Biotherapeutics Co. Ltd. has established new collaborations with Umoja Biopharma Inc. for the development and commercialization of novel ex vivo and in vivo cell and gene therapies. These collaborations seek to advance off-the-shelf cell and gene therapies with applications in oncology and immunology.
Radiotherapy resistance and metastasis are among the top risk factors for refractory oral squamous cell carcinoma (OSCC), the mechanisms of which must be elucidated, plus there is a lack of biomarkers to predict response.
Remix Therapeutics Inc. has closed a $60 million financing to advance its lead program, REM-422, into the clinic and for further advancement of a pipeline of RNA processing targeted therapeutics.
Sail Biomedicines Inc. has received two grants from the Bill & Melinda Gates Foundation to advance the company's Endless RNA (eRNA) platform to develop secreted monoclonal antibodies and vaccines for malaria.
Researchers from Guandong Pharmaceutical University reported on the synthesis and preclinical characterization of a series of novel long-acting peroxisome proliferator-activated receptor (PPAR) pan-agonists targeting PPARα, PPARδ, and PPARγ with lipid-regulating effects. PPARs are involved in lipid and lipoprotein metabolism, thus targeting the PPARs system is a promising strategy for the management of metabolic syndrome.
Researchers from Baylor University and collaborators have described the synthesis and evaluation of a series of 6-aryl-3-aroyl-indole analogues acting as tubulin polymerization inhibitors aimed to be used as anticancer agents. Inhibitors of tubulin polymerization are promising antiproliferative agents and their interaction with the colchicine site is linked to its activity as vascular disrupting agents (VDAs).
RSS
